Burning Rock Biotech (BNR) Cash & Equivalents (2019 - 2025)

Burning Rock Biotech's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $67.4 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 6.8% year-over-year to $67.4 million; the TTM figure through Dec 2025 stood at $67.4 million (down 6.8% YoY), while the FY2025 annual figure was $68.4 million, down 3.95% from the prior year.
• Cash & Equivalents was $67.4 million for Q4 2025 at Burning Rock Biotech, up from $65.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $318.3 million in Q1 2021 to a low of $63.2 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $133.9 million across 5 years, with a median of $94.1 million in 2023.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents jumped 509.29% in 2021, then plunged 43.6% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $223.9 million in 2021, then sank by 43.13% to $127.3 million in 2022, then plunged by 32.9% to $85.4 million in 2023, then fell by 15.29% to $72.4 million in 2024, then retreated by 6.8% to $67.4 million in 2025.
• The last three Cash & Equivalents figures came in at $67.4 million (Q4 2025), $65.2 million (Q3 2025), and $63.2 million (Q2 2025), per Business Quant data.